<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The Cilostazol <z:hpo ids='HP_0001297'>Stroke</z:hpo> Prevention Study II has shown a similar efficacy in <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention but markedly fewer hemorrhagic events with the <z:chebi fb="0" ids="50218">phosphodiesterase inhibitor</z:chebi> cilostazol versus aspirin </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study is therefore to investigate how cilostazol affects cerebral hemodynamics and whether it prevents hemorrhagic transformation induced by recombinant tissue plasminogen activator (rtPA) in a mouse model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Particular emphasis will be placed on the plasma-microvessel interface </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: After receiving food containing 0.3% cilostazol or standard food for 7 days, adult C57BL/6J mice were subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>/reperfusion with or without rtPA (10mg/kg) intravenously administered prior to reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Cerebral blood flow was monitored at several time points by laser speckle imaging in the 24 hour period post reperfusion, before neurobehavioral and histological assessment </plain></SENT>
<SENT sid="5" pm="."><plain>The long-term effect of cilostazol on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was analyzed in the non-rtPA cohort </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules (P-selectin and intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase </plain></SENT>
<SENT sid="7" pm="."><plain>Cilostazol significantly reduced mortality rate and improved motor function at 7 days post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>In the rtPA cohort, cilostazol significantly suppressed <z:hpo ids='HP_0000969'>edema</z:hpo> formation and hemorrhagic transformation with reduced density of microglial cells positive for matrix metalloproteinase-9 in the cerebral cortex and the striatum </plain></SENT>
<SENT sid="9" pm="."><plain>In both cohorts, cilostazol significantly suppressed focal no-reflow, mitigated cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath>, and improved neurological outcome </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Cilostazol may possess protective properties against cerebral ischemic injury by preventing no-reflow and hemorrhagic transformation, via maintenance of microvascular integrity </plain></SENT>
</text></document>